Voyager Therapeutics, Inc (VYGR) insider trading
Every open-market stock purchase and sale by Voyager Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders sold $335K over the last 12 months (12 sales). No open-market buys.
- Last insider buy: Neurocrine Biosciences Inc (10% owner), $39M, 3 years ago.
Last 12 months: insiders bought $0 (0 buys) and sold $335K (12 sales). Last close $3.37 on Jun 7, 2026.
Recent VYGR insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Jun 9, 2026 | George A Scangos (Director) | Bought (not open market) | — |
| Jun 9, 2026 | Glenn Pierce (Director) | Bought (not open market) | — |
| Jun 9, 2026 | Jude Onyia (Director) | Bought (not open market) | — |
| Jun 9, 2026 | Catherine J Mackey (Director) | Bought (not open market) | — |
| Jun 9, 2026 | Steven Hyman (Director) | Bought (not open market) | — |
| Jun 9, 2026 | Michael J Higgins (Director) | Bought (not open market) | — |
| Jun 9, 2026 | James A Geraghty (Director) | Bought (not open market) | — |
| Jun 9, 2026 | Nancy Vitale (Director) | Bought (not open market) | — |
| Jun 9, 2026 | Grace Colon (Director) | Bought (not open market) | — |
| Apr 2, 2026 | Alfred Sandrock (CEO) | Sold | $44.5K |
| Apr 1, 2026 | Gregory L. Shiferman (VP) | Bought (not open market) | — |
| Feb 24, 2026 | Alfred Sandrock (CEO) | Sold | $53.8K |
| Feb 24, 2026 | Robin Swartz (COO) | Sold | $24.3K |
| Feb 24, 2026 | Nathan D. Jorgensen (CFO) | Sold | $17.6K |
| Feb 24, 2026 | Todd Alfred Carter (C-suite exec) | Sold | $15.7K |
| Feb 18, 2026 | Alfred Sandrock (CEO) | Sold | $40K |
| Feb 18, 2026 | Robin Swartz (COO) | Sold | $13.4K |
| Feb 18, 2026 | Todd Alfred Carter (C-suite exec) | Sold | $11.4K |
| Feb 10, 2026 | Alfred Sandrock (CEO) | Sold | $46.1K |
| Feb 10, 2026 | Robin Swartz (COO) | Sold | $17.6K |
| Feb 10, 2026 | Todd Alfred Carter (C-suite exec) | Sold | $13.6K |
| Feb 6, 2026 | Todd Alfred Carter (C-suite exec) | Bought (not open market) | — |
| Feb 6, 2026 | Todd Alfred Carter (C-suite exec) | Bought (not open market) | — |
| Feb 6, 2026 | Alfred Sandrock (CEO) | Bought (not open market) | — |
| Feb 6, 2026 | Toby Ferguson (C-suite exec) | Bought (not open market) | — |
Who's trading VYGR
- Nancy Vitale, Director: other filings, last Jun 9, 2026
- Grace Colon, Director: other filings, last Jun 9, 2026
- James A Geraghty, Director: other filings, last Jun 9, 2026
- Michael J Higgins, Director: other filings, last Jun 9, 2026
- Steven Hyman, Director: other filings, last Jun 9, 2026
- Catherine J Mackey, Director: other filings, last Jun 9, 2026
- Jude Onyia, Director: other filings, last Jun 9, 2026
- Glenn Pierce, Director: other filings, last Jun 9, 2026
- George A Scangos, Director: other filings, last Jun 9, 2026
- Alfred Sandrock, CEO: sold $184K (4 sales), last Apr 2, 2026
- Gregory L. Shiferman, VP: other filings, last Apr 1, 2026
- Robin Swartz, COO: sold $55.3K (3 sales), last Feb 24, 2026
- Todd Alfred Carter, C-suite exec: sold $40.6K (3 sales), last Feb 24, 2026
- Nathan D. Jorgensen, CFO: sold $54.2K (2 sales), last Feb 24, 2026
- Toby Ferguson, C-suite exec: other filings, last Feb 6, 2026
Get free alerts when an insider at Voyager Therapeutics, Inc files a new trade →